Beyond bevacizumab: Investigating new angiogenesis inhibitors in ovarian cancer

Expert Opinion on Investigational Drugs

Volumn 23, Issue 1, 2014, Pages 37-53

  Tomao, Federica ^a   Papa, Anselmo ^a   Rossi, Luigi ^a   Caruso, Davide ^a   Zoratto, Federica ^a   Benedetti Panici, Pierluigi ^a   Tomao, Silverio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Aflibercept; Angiogenesis; Bevacizumab; Chemotherapy; Epithelial ovarian cancer; Tyrosine kinase inhibitors; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; BRIVANIB; CABOZANTINIB; CARBOPLATIN; CEDIRANIB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ENMD 2079; FIBROBLAST GROWTH FACTOR; GEMCITABINE; IMATINIB; NINTEDANIB; OMBRABULIN; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TOPOTECAN; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR TARGETING AGENT; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB; VOLOCIXIMAB;

ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; APOPTOSIS; BLOOD VESSEL PERMEABILITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CYTOKINE RELEASE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ELECTROLYTE DISTURBANCE; FATIGUE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOKALEMIA; LEUKOPENIA; LIVER TOXICITY; NEUTROPENIA; OVARY CARCINOMA; OVERALL SURVIVAL; PAIN; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOSIS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS;

EID: 84889783720     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.839657     Document Type: Review

References (151)

1. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2013. CA Cancer J Clin 2013;63(1):11-30
2. Ghasemi R, Grassadonia A, Tinari N, et al. Tumor-derived microvesicles: the metastasomes. Med Hypotheses 2013;80(1):75-82
3. Fleming GF, Ronnet BM, Seidman J, et al. Epithelial ovarian cancer. Principles and practice of gynecologic oncology. 5th edtion. Lippincot Williams & Wilkins; Philadelphia; 2009. p. 763-836
4. Kusumbe A, Bapat S. Ovarian stem cell biology and the emergence of ovarian cancer stem cells, in cancer stem cells: identification and targets. Bapat S, editor. John Wiley & Sons, Inc., Hoboken, NJ, USA. 2008; doi: 10.1002/9780470391594.ch6
5. Ozols RF. Update on the management of ovarian cancer. Cancer J 2002;8(Suppl 1):S22-30
6. Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatinbased intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991;9(10):1801-5
7. Pisano C, Bruni GS, Facchini G, et al. Treatment of recurrent epithelial ovarian cancer. Ther Clin Risk Manag 2009;5(4):421-6
8. Tomao F, Panici PB, Frati L, et al. Emerging role of pemetrexed in ovarian cancer. Expert Rev Anticancer Ther 2009;9(12):1727-35
9. Benedetti-Panici P, Perniola G, Marchetti C, et al. Intraperitoneal chemotherapy by ultrasound-guided direct puncture in recurrent ovarian cancer: feasibility, compliance, and complications. Int J Gynecol Cancer 2012;22(6):1069-74
10. Bellati F, Napoletano C, Gasparri ML, et al. Current knowledge and open issues regarding bevacizumab in gynecological neoplasms. Crit Rev Oncol Hematol 2012;83(1):35-46
11. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-96
12. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-83
13. Garcia A, Singh H. Bevacizumab and ovarian cancer. Ther Adv Med Oncol 2013;5(2):133-41
14. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039-45
15. Tomao F, Tomao S, Panici PB, et al. Improvement in progression free survival in OCEANS bevacizumab arm: a critical point of view. J Clin Oncol 2013;31(1):166-7
16. Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012;30:LBA5002
17. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
18. Folkman J. What is the evidence that tumors are angiogenesis dependent J Natl Cancer Inst 1990;82(1):4-6 (Pubitemid 20020880)
19. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74 (Pubitemid 43093963)
20. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62 (Pubitemid 40093472)
21. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9 (Pubitemid 32937367)
22. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995;147(1):9-19
23. Stone PJ, Goodheart MJ, Rose SL, et al. The influence of microvessel density on ovarian carcinogenesis. Gynecol Oncol 2003;90(3):566-71
24. Palmer JE, Sant Cassia LJ, Irwin CJ, et al. Prognostic value of measurements of angiogenesis in serous carcinoma of the ovary. Int J Gynecol Pathol 2007;26(4):395-403 (Pubitemid 47476324)
25. Gadducci A, Ferrero A, Cosio S, et al. Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable.Anticancer Res. 2006;26(5B):3925-32 (Pubitemid 44701480)
26. Taskiran C, Erdem O, Onan A, et al. The prognostic value of endoglin (CD105) expression in ovarian carcinoma. Int J Gynecol Cancer 2006;16(5):1789-93 (Pubitemid 44470037)
27. Rubatt JM, Darcy KM, Hutson A, et al. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: a Gynecologic Oncology Group study. Gynecol Oncol 2009;112(3):469-74
28. Henriksen R, Gobl A, Wilander E, et al. Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGFbeta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest 1995;73:213-20
29. Fu Y, Lai Y, Wang Q, et al. Overexpression of clusterin promotes angiogenesis via the vascular endothelial growth factor in primary ovarian cancer. Mol Med Rep 2013;7(6):1726-32
30. Karamysheva AF. Mechanism of angiogenesis. Biochemistry (Mosc) 2008;73(7):751-62
31. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3(6):401-10 (Pubitemid 37328844)
32. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23(5):1011-27 (Pubitemid 46202320)
33. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9(Suppl 1):2-10 (Pubitemid 38747842)
34. Fischer C, Mazzone M, Jonckx B, et al. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy Nat Rev Cancer 2008;8:942-56
35. Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011;121:230-8
36. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-84 (Pubitemid 36749216)
37. Martin L, Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol 2007;25(20):2894-901 (Pubitemid 47123153)
38. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases tie-1 and tie-2 in blood vessel formation. Nature 2002;376:70-4
39. Barnett B, Krysczek I, Cheng P, et al. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 2005;54:369-77 (Pubitemid 41748714)
40. Kim R, Emi M, Tanabe K. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive network for tumor immunity. Immunology 2006;119:254-64 (Pubitemid 44401644)
41. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803 (Pubitemid 37328914)
42. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8:579-91
43. Ramakrishnan S, Subramanian IV, Yokoyama Y, et al. Angiogenesis in normal and neoplastic ovaries. Angiogenesis 2005;8(2):169-82 (Pubitemid 41712846)
44. Chen H, Ye D, Xie X, et al. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol 2004;94:630-5 (Pubitemid 39194453)
45. Soker S, Takashima S, Miao HQ, et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735-45 (Pubitemid 28155313)
46. Osada R, Horiuchi A, Kikuchi N, et al. Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas. Hum Pathol 2006;37:1414-25 (Pubitemid 44584330)
47. Korn EL, Freidlin B, Abrams JS. Overall survival as the outcome of randomized clinical trials with effective subsequent therapies. J Clin Oncol 2011;29:2439-42
48. Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009;100:1-7
49. Bellati F, Napoletano C, Gasparri ML, et al. Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms. Crit Rev Oncol Hematol 2011;83(1):35-46
50. Papamichail M, Perez SA, Gritzapis AD, et al. Natural killer lymphocytes: biology, development and function. Cancer Immunology. Immunotherapy 2004;53:176-86
51. Dikov MM, Ohm JE, Ray N, et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 2005;174:215-22 (Pubitemid 40007407)
52. Lissoni P, Malugani F, Bonfanti A, et al. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J Biol Regul Homeost Agents 2001;15:140-4 (Pubitemid 32717550)
53. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1(10):1024-8
54. Kassim SK, El-Salahy EM, Fayed ST, et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 2004;37(5):363-9 (Pubitemid 38490454)
55. Cooper BC, Ritchie JM, Broghammer CL, et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res 2002;8(10):3193-7 (Pubitemid 35155030)
56. Boss EA, Massuger LF, Thomas CM, et al. Vascular endothelial growth factor in ovarian cyst fluid. Cancer 2001;91:371-7 (Pubitemid 32099239)
57. Paley PJ, Staskus KA, Gebhard K, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997;80(1):98-106 (Pubitemid 27270925)
58. Hefler LA, Zeillinger R, Grimm C, et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol 2006;103(2):512-17 (Pubitemid 44740099)
59. Li L, Wang L, Zhang W, et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res 2004;24:1973-9 (Pubitemid 38954620)
60. Rusnati M, Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des 2007;13:2025-44 (Pubitemid 47040487)
61. Lu C, Han HD, Mangala LS, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010;18(2):185-97
62. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17:1359-70
63. Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 2007;101:59-68 (Pubitemid 47094624)
64. Plummer PN, Freeman R, Taft R, et al. MicroRNAs regulate tumor angiogenesis modulated by endothelial progenitor cells. Cancer Res 2013;73(1):341-52
65. Sasahira T, Kurihara M, Bhawal UK, et al. Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer. Br J Cancer 2012;107:700-6
66. Staszel T, Zapala B, Polus A, et al. Role of microRNAs in endothelial cell pathophysiology. Pol Arch Med Wewn 2011;121:361-6
67. Nam EJ, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008;14:2690-5
68. He J, Jing Y, Li W, et al. Roles and mechanism of miR-199a and miR-125b in tumor angiogenesis. PLoS One 2013;8(2):e56647
69. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76 (Pubitemid 36749215)
70. Lin YG, Han LY, Kamat AA, et al. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 2007;109(2):332-40 (Pubitemid 46106248)
71. Hinnen P, Eskens FA. Vascular disrupting agents in clinical development. Br J Cancer 2007;96(8):1159-65 (Pubitemid 46625071)
72. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci 2002;99:11393-8 (Pubitemid 34920936)
73. Coleman RL, Duska LR, Ramirez PT, et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 2011;12:1109-17
74. Gotlieb WH, Amant F, Advani S, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2012;13(2):154-62
75. Moroney JW, Sood AK, Coleman RL. Aflibercept in epithelial ovarian carcinoma. Future Oncol 2009;5(5):591-600
76. Tew CN, Ray-Coquard I, Oza A, et al. VEGF-Trap for patients with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter Phase II study [abstract 5508]. Proceedings of the American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; 2007
77. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28:780-7
78. Lee JW, Han HD, Shahzad MM, et al. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2009;101(17):1193-205
79. Delmonte A, Del Conte G, Sessa C, et al. Results from a phase 1/2 study of volociximab in combination with liposomal doxorubicin in relapsed advanced epithelial ovarian and primary peritoneal carcinoma. J Clin Oncol 2008;26(May 20 Suppl):abstract 16527
80. Coxon A, Bready J, Min H, et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 2010;9:2641-51
81. Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2012;30:362-71
82. Calcinotto A, Grioni M, Jachetti E, et al. Targeting TNF-a to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J Immunol 2012;188:2687-94
83. Curnis F, Sacchi A, Borgna L, et al. Enhancement of tumour necrosis factor alpha antitumour immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000;18:1185-90
84. Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumours by vascular targeting and barrier alteration. J Clin Invest 2002;475-82 (Pubitemid 34919701)
85. Lorusso D, Scambia G, Amadio G, et al. Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients. Br J Cancer 2012;107:37-42
86. Available from: www.clinicaltrial.gov NCT01358071
87. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109 (Pubitemid 39331023)
88. Polcher M, Eckhardt M, Coch C, et al. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemother Pharmacol 2010;66:203-7
89. Matei D, Sill MW, Lankes HA, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group trial. J Clin Oncol 2011;29(1):69-75
90. Bodnar L, Górnas M, Szczylik C. Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. Gynecol Oncol 2011;123(1):33-6
91. Ramasubbaiah R, Perkins SM, Schilder J, et al. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecol Oncol 2011;123:499-504
92. Welch SA, Hirte HW, Elit L, et al. Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. Int J Gynecol Cancer 2010;20(5):787-93
93. Kohn EC, Lee J, Annunziata CM, et al. A phase II study of intermittent sorafenib with bevacizumab in bevacizumab-näve epithelial ovarian cancer (EOC) patients. J Clin Oncol 2011;29:abstract5019
94. Thompson DS, Dudley BS, Bismayer JA, et al. Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute. 2013 ASCO annual meeting. J Clin Oncol 2013;31(Suppl): abstract 5513
95. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37 (Pubitemid 36109749)
96. Baumann KH, du Bois A, Meier W, et al. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann Oncol 2012;23:2265-71
97. Hilberg F, Roth GJ, Krssak M, et al. BIBF, 1120, triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-82
98. Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011;29:3798-804
99. Available from: www.clinicaltrial.gov NCT01015118
100. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6:2012-21 (Pubitemid 47052491)
101. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15:4220-7
102. Friedlander M, Hancock KC, Rischin D, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010;119:32-7
103. Du Bois A, Floquet A, Kim JW, et al. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an International Intergroup trial (AGOOVAR16). J Clin Oncol ASCO Annual Meeting 2013;31(Suppl):abstract: LBA5503
104. Lindsay CR, MacPherson IR, Cassidy J. Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncol 2009;5:421-32
105. Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009;27:5601-6
106. Hirte HW, Vidal L, Fleming GF, et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial. J Clin Oncol 2008;26:abstract 5521
107. Raja FA, Griffin CL, Qian W. Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. Br J Cancer 2011;105:884-9
108. Schroder W, Witteveen E, Abadie S, et al. A phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 in combination with paclitaxel and carboplatin in patients (PTs) with stage IIC to IV epithelial ovarian cancer [abstract]. 2007 ASCO Ann Meet Proc (Post-Meet Ed). J Clin Oncol 2005;23(16S June 1 Suppl):5042
109. Juretzka MM, Aghajanian C, Hensley ML, et al. Phase I trial of PTK787/ZK222584 (PTK/ZK) in combination with carboplatin (C) and paclitaxel (T) in platinum-sensitive recurrent epithelial ovarian (EOC), fallopian tube (FT), or primary peritoneal (PPC) cancers [abstract]. 2007 ASCO Ann Meet Proc (Post-Meet Ed). J Clin Oncol 2007;25(18S June 20 Suppl):5564
110. Fletcher GC, Brokx RD, Denny TA, et al. ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther 2011;10(1):126-37
111. Matulonis UA, Lee J, Lasonde B, et al. ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer 2013;49(1):121-31
112. Buchdunger E, Zimmermann J, Mett H, et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA 1995;92:2558-62
113. Matei D, Emerson RE, Schilder J, et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis. Cancer 2008;15:113-14
114. Russel J, Schilder RJ, Sill MW, et al. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2008;26:3418-25
115. Bhide RS, Cai ZW, Zhang YZ, et al. Discovery and preclinical studies of (R)-1-(4-(4-fluoro 2-methyl-1Hindol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4] triazin-6-yloxy)propan-2-ol(BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 2006;2143-6
116. Marathe PH, Kamath AV, Zhang Y, et al. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemother Pharmacol 2009;65:55-66
117. Kaye SB, Siu LL, Jassem J, et al. Brivanib (B) in advanced ovarian cancer (Oc): subset results of a phase 2 randomized discontinuation trial (Rdt). 37th Congress of the European-Societyfor-Medical-Oncology (ESMO). Ann Oncol 2012;23(Suppl 9):319
118. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298-08
119. Schimmoller F, Zayzafoon M, Chung LWK, et al. Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone [abstract]. Mol Cancer Ther 2011;10(Suppl):233
120. Buckanovich RJ, Berger R, Sella A, et al. Results from a phase II randomized discontinuation trial. J Clin Oncol ASCO Annual Meeting 2011;29: abstract 5008
121. Horsman MR, Siemann DW. Pathophysiologic effects of vascular targeting agents and the implications for combination with conventional therapies. Cancer Res 2006;66(24):11520-39 (Pubitemid 46094158)
122. Zweifel M, Jayson GC, Reed NS, et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 2011;22(9):2036-41
123. Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007;21:1050-63 (Pubitemid 46686474)
124. Miranda TB, Cortez CC, Yoo CB, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 2009;8:1579-88
125. McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012;492:108-12
126. Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012;8:890-6
127. Qi W, Chan H, Teng L, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA 2012;109:21360-5
128. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423-35 (Pubitemid 40791485)
129. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27 (Pubitemid 38173977)
130. Kim TJ, Ravoori M, Landen CN, et al. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res 2007;67:9337-45 (Pubitemid 47535923)
131. Birrer MJ, Bondarenko I, Tjulandin S, et al. A phase II placebo (Pbo)-controlled randomized study of ombrabulin in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with carboplatin (Cb) and paclitaxel (P). J Clin Oncol 2013;31(Suppl):abstract 5516
132. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospitalphase II consortia. J Clin Oncol 2008;26(1):76-82
133. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25(33):5180-6 (Pubitemid 350232248)
134. Micha JP, Goldstein BH, Rettenmaier MA, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 2007;17(4):771-6 (Pubitemid 47063333)
135. Penson RT, Dizon DS, Cannistra SA, et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 2010;28(1):154-9
136. Rose PG, Drake R, Braly PS, et al. Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. J Clin Oncol 2009;27(15 Suppl): abstract 5546
137. Konner JA, Grabon DM, Gerst SR, et al. Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plusbevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer. J Clin Oncol 2011;29(35):4662-8
138. Tillmanns TD, Lowe MP, Schwartzberg LS, et al. A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinumresistant primary epithelial ovarian or primary peritoneal carcinoma. J Clin Oncol 2010;28(15 Suppl):abstract 5009
139. Horowitz NS, Penson RT, Duda DG, et al. Safety, efficacy, and biomarker exploration in a phase II study of bevacizumab, oxaliplatin, and gemcitabine in recurrent müllerian carcinoma. Clin Ovarian Cancefr Other Gynecol Malig 2011;4(1):26-33
140. Van Cutsem E, Khavat D, Verslype C, et al. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours. Eur J Cancer 2013;49(1):17-24
141. Isambert N, Frever G, Zanetta S, et al. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 2012;18(6):1743-50
142. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28:780-7
143. Herbst RS, Hong D, Chap L, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009;27(21):3557-65
144. Siu LL, Awada A, Takimoto CH, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006;12(1):144-51 (Pubitemid 43166188)
145. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24(1):25-35 (Pubitemid 46630490)
146. Biagi JJ, OZa AM, Chalcal HI, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 2011;22(2):335-40
147. Du Bois A, Huober J, Stopfer P, et al. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol 2010;21(2):370-5
148. Matulonis UA, Lee J, Lasonde B, et al. ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer 2013;49(1):121-31
149. Alberts DS, Liu PY, Wilczynski SP, et al. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int J Gynecol Cancer 2007;17(4):784-8 (Pubitemid 47063331)
150. Coleman RL, Broaddus RR, Bodurka DC, et al. Phase II trial of imatinib mesylate in patients with recurrent platinum-and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 2006;101(1):126-31
151. Posadas EM, Kwitkowski V, Kotz HL, et al. A prospective analysis of imatinibinduced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer 2007;110(2):309-17 (Pubitemid 47121890)